TY - JOUR
T1 - Mortality among patients with giant cell arteritis
T2 - A large-scale population-based cohort study
AU - Ben-Shabat, Niv
AU - Tiosano, Shmuel
AU - Shovman, Ora
AU - Comaneshter, Doron
AU - Shoenfeld, Yehuda
AU - Cohen, Arnon D.
AU - Amital, Howard
N1 - Publisher Copyright:
Copyright © 2020. All rights reserved.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Objective. Studies regarding mortality among patients with giant cell arteritis (GCA) have yielded conflicting results. Thus in this large population-based study we aimed to examine whether GCA is associated with increased mortality, and if so, the effect of age at diagnosis and sex on the association. Methods. We used the medical database of Clalit Health Services for this retrospective cohort study. Followup was from January 1, 2002, and continued until death or end of followup on September 1, 2018. Incident GCA patients were compared with age- and sex-matched controls. Estimated median survival times were calculated using the Kaplan-Meier method. HR for all-cause mortality were obtained by the Cox proportional hazard model, adjusted for sociodemographic variables and cardiovascular risk factors. Results. The study included 7294 patients with GCA and 33,688 controls. The mean age at start of followup was 72.1 ± 9.9 years with 69.2% females. Estimated median survival time was 13.1 years (95% CI 12.6-13.5) in patients with GCA compared with 14.4 years (95% CI 14.1-14.6) in controls (p < 0.001). The multivariate analysis demonstrated increased mortality risk in the first 2 years after diagnosis (HR 1.14, 95% CI 1.04-1.25) and > 10 years after diagnosis (HR 1.14, 95% CI 1.02-1.3). The mortality risk was higher in patients diagnosed at ≤ 70 years of age [HR 1.5 (95% CI 1.14-1.99) 0-2 yrs; HR 1.38 (95% CI 1.1-1.7) > 10 yrs]. Conclusion. Patients with GCA have a minor decrease in longterm survival compared to age- and sex-matched controls. The seen difference is due to excess mortality in the first 2 years, and > 10 years after diagnosis. Patients diagnosed ≤ 70 years of age are at greater risk.
AB - Objective. Studies regarding mortality among patients with giant cell arteritis (GCA) have yielded conflicting results. Thus in this large population-based study we aimed to examine whether GCA is associated with increased mortality, and if so, the effect of age at diagnosis and sex on the association. Methods. We used the medical database of Clalit Health Services for this retrospective cohort study. Followup was from January 1, 2002, and continued until death or end of followup on September 1, 2018. Incident GCA patients were compared with age- and sex-matched controls. Estimated median survival times were calculated using the Kaplan-Meier method. HR for all-cause mortality were obtained by the Cox proportional hazard model, adjusted for sociodemographic variables and cardiovascular risk factors. Results. The study included 7294 patients with GCA and 33,688 controls. The mean age at start of followup was 72.1 ± 9.9 years with 69.2% females. Estimated median survival time was 13.1 years (95% CI 12.6-13.5) in patients with GCA compared with 14.4 years (95% CI 14.1-14.6) in controls (p < 0.001). The multivariate analysis demonstrated increased mortality risk in the first 2 years after diagnosis (HR 1.14, 95% CI 1.04-1.25) and > 10 years after diagnosis (HR 1.14, 95% CI 1.02-1.3). The mortality risk was higher in patients diagnosed at ≤ 70 years of age [HR 1.5 (95% CI 1.14-1.99) 0-2 yrs; HR 1.38 (95% CI 1.1-1.7) > 10 yrs]. Conclusion. Patients with GCA have a minor decrease in longterm survival compared to age- and sex-matched controls. The seen difference is due to excess mortality in the first 2 years, and > 10 years after diagnosis. Patients diagnosed ≤ 70 years of age are at greater risk.
KW - GIANT CELL ARTERITIS
KW - MORTALITY
KW - SURVIVAL
KW - TEMPORAL ARTERITIS
KW - VASCULITIS
UR - http://www.scopus.com/inward/record.url?scp=85084802381&partnerID=8YFLogxK
U2 - 10.3899/jrheum.190927
DO - 10.3899/jrheum.190927
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 31839591
AN - SCOPUS:85084802381
SN - 0315-162X
VL - 47
SP - 1385
EP - 1391
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 9
ER -